I can't tell how soon after the stroke this was implemented so I don't know whether this is hyperacute or acute. Thats what your doctor is for.
http://www.digitaljournal.com/pr/1108379
Tarix Pharmaceuticals, a biopharmaceutical company focused on
developing novel, peptide-based therapies to treat a range of critical
medical conditions, today announced it has uncovered a new role for its
therapeutic peptides in stimulating revascularization following
ischemia.
In models of ischemic stroke and peripheral vascular disease,
treatment with either the Company's natural peptide, TXA127, or its
cyclic analog, PanCyte, resulted in increased blood flow and histologic
evidence of vasculogenesis (new blood vessel formation).
Rick Franklin, CEO of Tarix
Pharmaceuticals, stated, "We explored the therapeutic value of our
peptides following ischemia, due to their stimulatory effect on
endothelial progenitor cells, which are increased naturally during
ischemia and play an important role in vascular regeneration. We were
very pleased, and somewhat surprised, at the efficacy seen in these
models in which we saw a return to near-normal blood flow that
correlated with histologic evidence of new vessel formation. In
addition, in multiple models of ischemic stroke recovery, there was
significant improvement in a variety of clinically relevant neurologic
measurements."
Franklin continued, "Given this compelling data, we are now planning
to initiate clinical trials in ischemic stroke and peripheral vascular
disease in 2013."
The transient middle cerebral artery occlusion stroke model involved
fifteen animals per treatment group, and was randomized and blinded.
There were significant improvements in neurologic score, forelimb
placement, stepping test and body swing test, all of which are standard
measurements of functional response in stroke. Treatment was begun
twenty-four hours after the stroke, and positive results were detectable
within two weeks, and improvement continued throughout the seven-week
study. In addition, there was a substantial increase in cerebral blood
flow and histologic evidence of new blood vessel formation.
Separately, in a mouse model of unilateral hindlimb ischemia,
ischemic recovery was compared between TXA127 or PanCyte treatment
versus control animals. Blood flow in treated animals improved
significantly faster toward normal, with percent blood flow more than
double that of control animals by day 49 (~85% vs ~40%). Histologic
examination again showed a significant increase in the number of
functional blood vessels amongst treated animals compared to controls.
About Tarix PharmaceuticalsTarix Pharmaceuticals is a
biopharmaceutical company focused on developing novel, peptide-based
therapies to treat a range of critical medical conditions. Tarix'
proprietary technology platform consists of TXA127, a pharmaceutical
formulation of the naturally occurring peptide, Angiotensin (1-7), and
PanCyte, a cyclic analogue of TXA127 with an extended half-life. TXA127
and PanCyte have shown striking effects in models of ischemic stroke
and peripheral vascular disease through improvement in endothelial
progenitor cell number and function. The peptides have also been
effective in models of diabetes. Tarix intends to initiate clinical
trials in these indications during 2013, adding to its clinical pipeline
that includes multiple programs in hematopoiesis.
Use the labels in the right column to find what you want. Or you can go thru them one by one, there are only 29,112 posts. Searching is done in the search box in upper left corner. I blog on anything to do with stroke.DO NOT DO ANYTHING SUGGESTED HERE AS I AM NOT MEDICALLY TRAINED, YOUR DOCTOR IS, LISTEN TO THEM. BUT I BET THEY DON'T KNOW HOW TO GET YOU 100% RECOVERED. I DON'T EITHER, BUT HAVE PLENTY OF QUESTIONS FOR YOUR DOCTOR TO ANSWER.
Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.
What this blog is for:
My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.
Tuesday, March 5, 2013
Tarix Pharmaceuticals' Peptide Technology Stimulates Revascularization Following Ischemia
Labels:
angiogenesis,
blood flow,
doctor question,
mice,
peptide,
TXA127
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment